On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety

Leading US medical organizations and experts have issued recommendations on COVID-19, flu and RSV vaccines ahead of the 2026–27 winter season.

Developed with the University of Minnesota’s Vaccine Integrity Project and the American Medical Association (AMA), the recommendations were published in JAMA.

The guidance aims to help doctors and patients make vaccination decisions and reduce the risk of severe respiratory illness.

What Do The 2026 Recommendations Say?

Flu Vaccine

• Children: Annual vaccination from 6 months of age.
• Adults 19–64: Annual vaccination.
• Adults 65+: Annual vaccination, with high-dose vaccine preferred.
• Pregnancy: Annual vaccination; avoid the nasal-spray vaccine.
• Immunocompromised: Annual vaccination from 6 months; avoid nasal-spray vaccine.
• Healthcare personnel: Annual vaccination.

RSV Vaccine

• Infants: All infants under 8 months who did not receive protection through vaccination during pregnancy.
• Children 8–19 months: Vaccination for those in certain risk groups.
• Adults 50–74: One-time vaccination for those at increased risk of severe RSV.
• Adults 75+: One-time vaccination.
• Pregnancy: One-time vaccination during the first eligible pregnancy, at 32–36 weeks, between September 1 and March 1.
• Immunocompromised adults 18+: Single dose; those under 18 should use shared decision-making.

COVID-19 Vaccine

• Children 6–23 months: Annual updated vaccination.
• Children 2–18: Annual vaccination for certain risk groups or if desired.
• Adults 19–64: Annual updated vaccination.
• Adults 65+: Annual updated vaccination, followed by a second dose six months later.
• Pregnancy: Annual updated vaccination.
• Immunocompromised: Annual updated vaccination from 6 months of age.
• Healthcare personnel: Annual updated vaccination.

CDC Has Not Issued New COVID, RSV Guidance

The recommendations come as the CDC has not issued new guidance for RSV or COVID-19 vaccination for the 2026–27 season.

The CDC updated its COVID-19 guidance last year, moving away from a broad recommendation and advising patients to consult a healthcare provider about vaccination.

For flu, the CDC updated its clinical guidance on Tuesday but said recommendations from the July 2025 immunisation schedule remain in effect for the 2026–27 season.

The updated flu guidance does not mention the first mRNA flu vaccine, which was approved by the FDA last month for older adults.

Respiratory Viruses Continue To Pose Risks

• Flu: During 2025–26, interim CDC estimates indicated at least 390,000 hospitalisations and 24,000 deaths.
• COVID-19: The virus is less severe than during the pandemic but continues to affect older adults, infants, pregnant women and immunocompromised people. It was associated with an estimated 4.6 million–12.9 million illnesses, 140,000–240,000 hospitalisations and 15,000–42,000 deaths.
• RSV: Infants and older adults remain at greatest risk of severe disease. RSV caused an estimated 2.8 million–5.8 million outpatient visits, 170,000–340,000 hospitalisations and up to 25,000 deaths.

What Did The Vaccine Evidence Show?

• Flu: A review of 5,800+ studies found vaccination reduced hospitalisation and mortality among high-risk groups. High-dose vaccines provided greater protection against hospitalisation in older adults. No new safety concerns were identified.
• COVID-19: Of 11,000+ studies screened, 155 met the review criteria. Updated vaccines continued to protect against hospitalisation, intensive care admission and death, particularly among older and high-risk groups. No new safety concerns were found in comparative studies.
• RSV: Of 2,000+ studies assessed, 75 were included. Vaccination reduced severe illness and hospitalisation among older adults and pregnant women, while nirsevimab reduced severe RSV illness in infants. No new safety concerns were identified.

Experts Call For Clear Vaccine Guidance

Bruce Gellin of the Vaccine Integrity Project said Americans should have access to the latest scientific evidence and recommendations from medical experts to make informed vaccination decisions.

“Whatever happens to the federal vaccine policy process, we cannot lower that scientific standard,” he said.

The potential benefits of Ivermectin and Mebendazole, two anti-parasitic drugs, for cancer treatment have sparked a debate.

A recent real-world study stated that an astonishing 84.4% clinical benefit rate was reported among cancer patients who took these two drugs together. But the number does not mean that 84% of the patients improved with the help of thesedrugs. The findings come with significant limitations.

Ivermectin-Mebendazole's Effects On Cancer Patients

Published in Anticancer Research in June 2026, the study followed 197 cancer patients who had been prescribed ivermectin and mebendazole off-label through a US telemedicine platform.

The patients received compounded capsules containing 25 mg of ivermectin and 250 mg of mebendazole. But only 122 patients, or 61.9%, completed the six-month follow-up.

Among those who completed follow-up, 48.4% of the patients had no tumour regression or no sign of the disease. Another 36.1% showed no change, while in 15.6% of the patients, the disease had progressed. This generated the study's 84.4% Clinical Benefit Ratio.

So, the number should not be interpreted as 84% of patients had their cancer tumours shrink or the disease disappeared.

The researchers also reported that 25.4% of participants faced side effects, most of which were mild and mainly gastrointestinal.

It is also important to note that patients were also receiving other treatments, including chemotherapy, radiation, and surgery, while nearly half reported using supplements. Many also made changes to their diets.

Also read: Daraxonrasib: New Drug Approved For Pancreatic Cancer Shows Promise In Lung Cancer Treatment

The Study Has Limitations

This was a prospective observational study, not a randomised controlled clinical trial. There was no comparison group receiving standard treatment or a placebo.

The cancer results were also self-reported through digital surveys rather than independently verified as part of the study.

That makes it impossible to determine whether ivermectin and mebendazole caused the reported improvements.

Patients were also receiving other cancer treatments and making changes to their diets or taking supplements. These factors could have influenced the outcomes.

PubMed currently carries an 'Expression of Concern' for the paper, dated June 9, 2026. The study's own authors describe their findings as “hypothesis-generating” and say randomized controlled trials are needed.

Also read: Blocked Ears After Flight Turned Out To Be Rare Head And Neck Cancer In 22-Year-Old

Ivermectin And Brain Cancer

Researchers are also exploring whether ivermectin can be delivered to brain tumours through the nose.

In a study in rats with glioma, ivermectin packed inside tiny nanocapsules and given through the nose reduced tumour size after 10 days.

The nano-formulation performed better than regular ivermectin, while another silica-based formulation did not have the same effect on the rats.

The idea is to use the nose as a possible route to help drugs reach the brain, where the blood-brain barrier can make drug delivery difficult.

However, this was an animal study. The results therefore show a potential research direction, not definite evidence that nasal ivermectin can treat brain cancer in humans.

Also read: Nearly 8 In 10 US Young Adults Show Signs Of Heart, Kidney Risk: Why Early Checks Matter

What Does The Evidence Say About Fenbendazole?

A 2025 case series described three people with advanced breast, prostate and melanoma cancers who self-administered fenbendazole alongside other treatments. The report described complete or near-complete remissions.

However, that paper was subsequently retracted in January 2026. PubMed now lists the retraction, making the original case series unsuitable as reliable evidence that fenbendazole treats cancer.

The study provides possible cancer treatment options that can be investigated treatment as they are not proven yet.

A 2025 review highlighted several possible anticancer mechanisms for ivermectin, including effects on YAP1, Wnt/TCF and AKT/mTOR signalling, oxidative stress and apoptosis.

But the review also noted that the human cases it examined were not designed to test ivermectin as a cancer treatment. So as of now, there is no robust clinical evidence that says ivermectin, mebendazole or fenbendazole as effective cancer treatments.

For cancer patients, these drugs should not be substituted for established treatment on the basis of these studies alone.

A cancer drug that was approved in the US just last week for pancreatic cancer is also showing promise in lung cancer treatment.

The drug, daraxonrasib (Rasonque), showed encouraging results in patients with previously treated RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. The results were published in the New England Journal of Medicine on September 2.

Rasonque is not approved for lung cancer yet. The new findings are early-stage evidence, and a larger Phase 3 trial is now underway.

More About This Drug

Pancreatic cancer is considered one of the most RAS-driven cancers, with more than 90% of patients carrying tumours driven by RAS protein mutations.

RAS mutations are found in about 30% of non-small cell lung cancers, making them among the most common cancer-driving alterations in the disease. Yet, apart from treatments targeting the specific KRAS G12C mutation, patients with other RAS mutations have had few treatment options.

Also read: Daraxonrasib: US FDA Approves Once-Daily Pill for Metastatic Pancreatic Cancer

What Did The Lung Cancer Trial Find?

The most relevant results came from 38 patients with NSCLC who received doses of 160 to 220 mg. These patients had already been treated with chemotherapy and immunotherapy but had not received docetaxel.

The tumours shrank in about 42% of patients. The duration of response was 11.5 months, while progression-free survival was 8.3 months and overall survival was 16 months.

For comparison, earlier studies of docetaxel in this treatment setting have reported response rates of around 9% to 14%, with progression-free survival of roughly 3 to 4.5 months.

As these results come from a small, early-stage study and are not a comparison with docetaxel, they need to be interpreted further cautiously.

Also read: Blocked Ears After Flight Turned Out To Be Rare Head And Neck Cancer In 22-Year-Old

Researchers React

David Hong, M.D., deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead investigator, said, “Immunotherapy has improved outcomes for many patients with non-small cell lung cancer, but the majority of these cancers eventually progress.”

“At that point, the few treatment options available to these patients often have modest clinical benefit and substantial toxicities, so these early results are encouraging.”

The drug did cause side effects. At the Phase 3-selected dose, 51% of patients experienced a grade 3 or higher adverse event, while 71% required dose modifications and 10% discontinued treatment. Rash was particularly common, affecting 90% of patients, while diarrhoea, nausea and vomiting were also reported.

Hong noted that “the toxicities are largely manageable compared to the alternatives available.”

The Drug Is Already Approved For Pancreatic Cancer

The interesting development comes shortly after the US FDA approved Rasonque on August 26, 2026. It is first targeted therapy in this new class for metastatic pancreatic adenocarcinoma.

In a 500-patient pancreatic cancer trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung and colon cancers.